Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has been given an average recommendation of “Hold” by the twenty-three ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $42.93.
PCRX has been the topic of several recent research reports. HC Wainwright set a $55.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 4th. Canaccord Genuity set a $46.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 4th. Royal Bank of Canada set a $54.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 4th. Wedbush reissued a “buy” rating and issued a $80.00 target price on shares of Pacira Pharmaceuticals in a report on Monday, November 20th. Finally, BidaskClub raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 29th.
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) traded down $0.11 during mid-day trading on Friday, reaching $32.14. The company had a trading volume of 820,250 shares, compared to its average volume of 1,018,951. The stock has a market capitalization of $1,298.70, a PE ratio of -29.63 and a beta of 1.95. Pacira Pharmaceuticals has a 12 month low of $29.35 and a 12 month high of $52.47. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.46. The company had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.09 earnings per share. equities research analysts predict that Pacira Pharmaceuticals will post -0.24 earnings per share for the current year.
In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.60% of the company’s stock.
Several large investors have recently made changes to their positions in the company. HealthCor Management L.P. lifted its holdings in shares of Pacira Pharmaceuticals by 8.6% during the fourth quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock valued at $127,820,000 after purchasing an additional 221,960 shares in the last quarter. Consonance Capital Management LP lifted its holdings in shares of Pacira Pharmaceuticals by 16.1% during the fourth quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock valued at $73,147,000 after purchasing an additional 222,200 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Pacira Pharmaceuticals by 5.3% during the third quarter. Westfield Capital Management Co. LP now owns 1,285,850 shares of the company’s stock valued at $48,284,000 after purchasing an additional 64,510 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Pacira Pharmaceuticals by 9.7% during the fourth quarter. Macquarie Group Ltd. now owns 1,266,414 shares of the company’s stock valued at $57,812,000 after purchasing an additional 111,869 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its holdings in shares of Pacira Pharmaceuticals by 1.7% during the fourth quarter. Rock Springs Capital Management LP now owns 1,106,700 shares of the company’s stock valued at $50,521,000 after purchasing an additional 18,700 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://ledgergazette.com/2018/03/20/pacira-pharmaceuticals-inc-pcrx-receives-42-93-consensus-target-price-from-analysts.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.